Organogenesis Acquires Shire’s Dermagraft Amid Reimbursement Challenges
This article was originally published in The Gray Sheet
Executive Summary
Dublin-based Shire’s decision to sell Dermagraft and its assets to its competitor was made in light of substantial Medicare pay cuts that took effect this year based on policies in CMS’ 2014 hospital outpatient prospective payment system regulation.